The Cystic Fibrosis Foundation committed up to $58 million over six years in a project with Pfizer to develop drugs targeting the Delta F508 genetic mutation associated with the disease. The CFF retains rights to any drug candidate Pfizer discovers but chooses not to develop.
Cystic Fibrosis Foundation expands partnership with Pfizer
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan